Biopharma company, Zelluna Immunotherapy, and clinical stage biotech, Glycostem Therapeutics, have entered into a partnership focused on the development and manufacture of allogeneic T-cell receptor guided Natural Killer cell therapies for the treatment of cancer.
Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics.
A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.
Published on Oct. 29, 2019, the study focuses on the multidrug-resistant bacterium Pseudomonas aeruginosa (P. aeruginosa) and how it can be used to develop new and sustainable antibiotic treatments.
The partnership will center on the development and commercialization of DCR-HBVS, Dicerna’s investigational therapy in Phase I clinical development, using its proprietary RNAi platform technology.
The project will seek to deliver treatments for the underlying cause of cystic fibrosis through submitted proposals from potential collaborators.
Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.
The goal of the investment is for the cures to be made available across the globe, including in sub-Saharan Africa’s low-resource communities.
The therapy received positive results in a randomized, double-blind, placebo-controlled clinical trial in 34 adults with proven celiac disease.
Under the agreement, gene and cell therapy companies can go directly to Aldevron for NTC’s technology without acquiring a license from NTC.
The company will produce the anti-HER3 antibody drug HMBD-001for use within a clinical partnership between Cancer Research UK and Hummingbird Bioscience to test the agent in a Phase I trial.
The long-term agreement gives CombiGene the authority to manufacture and commercialize the drug if it is approved after clinical studies.
MilliporeSigma will now be the first company to make acoustic technology available for cell therapy manufacturing.
Manufacturing of the cell line will take place at Lonza’s GMP facility in Geleen, Netherlands.
The new incubators are set to be operational starting in 2021.
Researchers used advanced animal model lab tests to determine the new vector is 10 times more efficient at incorporating corrective genes into bone marrow stem cells than traditional vectors.
Automated, electronic systems for raw materials tracking improve efficiency and prevent mistakes in biopharma manufacturing.
The new program, Cornerstone, integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of gene therapy medicinal products.
The venture will focus on single-use and modular systems designed to develop novel biotherapeutics.
TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.
The companies plan to create a new curriculum focusing on single-use applications training, cell therapy technology, process efficiency strategies, process development methodologies, and chromatography proficiency.
Innovation in manufacturing technologies must occur to ensure the availability of gene therapies and cell therapies.
Innovate UK has awarded a grant worth thousands to the Atelerix Consortium for the collaborative work with the Cell and Gene Therapy Catapult and Rexgenero on development of cell stabilization technology.
Pfizer is investing $500 million for the construction of a state-of-the-art gene therapy manufacturing facility in Sanford, NC.
The companies have entered into a manufacturing agreement for the production of Phase III clinical trial material.
